Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN7A | Q01118 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.48 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.47 |
| ▸ | PIR | O00625 | 1/20 | 0.46 |
| ▸ | ACP1 | P24666 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4536226 | 0.93 | SCN7A (0.58) | SCN7AMEN1MAPTKMT2AEHMT2 | |
| SCHEMBL16620884 | 0.84 | SCN7A (0.52) | SCN7AMEN1MAPTKMT2AEHMT2 | |
| SCHEMBL16621242 | 0.83 | SCN7A (0.54) | SCN7AMEN1MAPTKMT2AEHMT2 | |
| Hydrochloric Acid SCHEMBL18109870 | 0.79 | PIR (0.53) | SCN7AMEN1MAPTKMT2AHRH3 | |
| Hydrochloric Acid SCHEMBL18109874 | 0.78 | PIR (0.54) | SCN7AHRH3PIR | |
| SCHEMBL4532061 | 0.77 | HDAC1 (0.38) | SCN7AMEN1MAPTKMT2A | |
| SCHEMBL16621374 | 0.77 | SCN7A (0.58) | SCN7AMEN1MAPTKMT2AEHMT2 | |
| SCHEMBL4541853 | 0.76 | SCN7A (0.44) | SCN7AMEN1MAPTKMT2A | |
| SCHEMBL16621435 | 0.76 | SCN7A (0.60) | SCN7AMEN1MAPTKMT2AHRH3 | |
| SCHEMBL25997216 | 0.76 | HRH3 (0.68) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264426-A1 | Bicyclic aromatic substituted pyridone derivative | MSD K.K. (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264426-A1 | Bicyclic aromatic substituted pyridone derivative | MSD K.K. (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264426-A1 | Bicyclic aromatic substituted pyridone derivative | MSD K.K. (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1939194-A1 | BICYCLIC AROMATIC SUBSTITUTED PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939194-A1 | BICYCLIC AROMATIC SUBSTITUTED PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264426-A1 | Bicyclic aromatic substituted pyridone derivative | PYCR1, CHRM1, MTR | SCN7A 4125/4885MEN1 183/4885MAPT 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.